Structural apelin analogues: Mitochondrial ROS inhibition and cardiometabolic protection in myocardial ischaemia reperfusion injury

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 2933-2945

  Pisarenko, Oleg ^a   Shulzhenko, Valentin ^a   Studneva, Irina ^a   Pelogeykina, Yulia ^a   Timoshin, Alexander ^a   Anesia, Rodica ^b,c   Valet, Philippe ^b,c   Parini, Angelo ^b,c   Kunduzova, Oksana ^b,c  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Université de Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; APELIN 12; APELIN 12 DERIVATIVE; APELIN 13; CARDIOVASCULAR AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; APELIN-12 PEPTIDE; APELIN-13 PEPTIDE; SIGNAL PEPTIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; ISOLATED HEART; MALE; MEMBRANE DAMAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ANIMAL; CARDIAC MUSCLE CELL; CELL MEMBRANE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MITOCHONDRION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; WISTAR RAT;

ANIMALS; APOPTOSIS; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MITOCHONDRIA; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84930197792     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13038     Document Type: Article

References (50)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Ames BN, Shigenaga MK, Hagen TM, (1995). Mitochondrial decay in aging. Biochim Biophys Acta 1271: 165-170.
5. 1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 46: 76-82.
6. Baines CP, (2011). The mitochondrial permeability transition pore and the cardiac necrotic program. Pediatr Cardiol 32: 258-262.
7. Bergmeyer HU, (1974). Methods of Enzymatic Analysis. Academic Press: New York, pp. 1510-2129.
8. Bergmeyer HU, Bernt E, (1974). Lactate dehydrogenase. UV-assay with pyruvate and NADH. In:, Bergmeyer HU, (ed.). Methods of Enzymatic Analysis. Academic Press: New York, pp. 574-578.
9. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, et al. (2005). Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112: 3297-3305.
10. Castan-Laurell I, Dray C, Knauf C, Kunduzova O, Valet P, (2012). Apelin, a promising target for type 2 diabetes treatment? Trends Endocrinol Metab 23: 234-241.
11. Chen JK, Chow SE, (2005). Antioxidants and myocardial ischemia: reperfusion injuries. Chang Gung Med J 28: 369-377.
12. Circu ML, Aw TY, (2010). Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762.
13. Dai T, Ramirez-Correa G, Gao WD, (2006). Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 553: 222-228.
14. Dickinson BC, Chang CJ, (2008). A targetable fluorescent probe for imaging hydrogen peroxide in the mitochondria of living cells. J Am Chem Soc 130: 11561-11562.
15. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buléon M, et al. (2008). Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 8: 437-445.
16. Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet PH, et al. (2010). Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett 584: 2363-2370.
17. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, et al. (2006). Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arter Thromb Vasc Biol 26: 1267-1272.
18. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, et al. (2010). Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121: 1818-1827.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kimura K, Miura S, Iwata A, Sugihara M, Arimura T, Nishikawa H, et al. (2009). Association between cardiac function and metabolic factors including adiponectin in patients with acute myocardial infarction. J Cardiol 53: 65-71.
21. Kleinz MJ, Baxter GF, (2008). Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 46: 271-277.
22. Kleinz MJ, Davenport AP, (2005). Emerging roles of apelin in biology and medicine. Pharmacol Therap 107: 198-211.
23. Korge P, Ping P, Weiss JN, (2008). Reactive oxygen species production in energized cardiac mitochondria during hypoxia/reoxygenation: modulation by nitric oxide. Circ Res 103: 873-880.
24. Lee DK, George SR, O'Dowd BF, (2006). Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 27: 190-194.
25. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
27. Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, et al. (2012). Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 33: 2360-2369.
28. Pisarenko OI, Shulzhenko VS, Pelogeykina YA, Studneva IM, Khatri DN, (2010). Apelin-12 improves metabolic and functional recovery of rat heart after global ischemia. Health 2: 927-934.
29. Pisarenko OI, Serebryakova LI, Studneva IM, Pelogeykina YA, Tskitishvili OV, Bespalova ZD, et al. (2013). Effects of structural analogues of apelin 12 in acute myocardial infarction in rats. J Pharmacol Pharmacother 4: 198-203.
30. Pisarenko OI, Lankin VZ, Konovalova GG, Serebryakova LI, Shulzhenko VS, Timoshin AA, et al. (2014). Apelin-12 and its structural analogue enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol Cell Biochem 391: 241-250.
31. Rastaldo R, Cappello S, Folino A, Berta GN, Sprio AE, Losano G, et al. (2011). Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol 300: H2308-H2315.
32. Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gielen S, et al. (2003). Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 5: 33-40.
33. Shin K, Pandey A, Liu XQ, Anini Y, Jan K, Rainey JK, (2013). Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity. FEBS Open Bio 3: 328-333.
34. Sidorova MV, Az'muko AA, Pal'keeva ME, Molokoedov AS, Bushuev VN, Dvoryantsev SN, et al. (2012). Synthesis and cardioprotective properties of apelin-12 and its structural analogues. Russ J Bioorg Chem 38: 40-45.
35. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC, (2007). Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 102: 518-528.
36. Smith CC, Yellon DM, (2011). Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 129: 206-219.
37. Smith SC, (2001). Primary and secondary prevention of heart disease: can we curb the global epidemic? Trans Am Clin Climatol Assoc 112: 89-95.
38. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. (2002). Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91: 434-440.
39. + circulating cells. Circ Res 111: 585-598.
40. Than A, Zhang X, Leow MK, Poh CL, Chong SK, Chen P, (2014). Apelin attenuates oxidative stress in human adipocytes. J Biol Chem 28: 4763-4774.
41. Tosaki A, Blasig IE, Pali T, Ebert B, (1990). Heart protection and radical trapping by DMPO during reperfusion in isolated working rat hearts. Free Radic Biol Med 8: 363-372.
42. Turer AT, Hill JA, (2010). Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 106: 360-368.
43. Tycinska AM, Sobkowicz B, Mroczko B, Sawicki R, Musial WJ, Dobrzycki S, et al. (2010). The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clin Chim Acta 411: 2014-2018.
44. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K, (2013). Adipocytokines in relation to cardiovascular disease. Metabolism 62: 1513-1521.
45. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843.
46. Wang M, Gupta RC, Rastogy S, Kohli S, Sabbah MS, Zhang K, et al. (2013a). Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail 19: 509-516.
47. Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, et al. (2013b). Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues. J Am Heart Assoc 2: e000249.
48. Weir RA, Chong KS, Dalzell JR, Petrie CJ, Murphy CA, Steedman T, et al. (2009). Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 11: 551-558.
49. Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, Tang CS, (2009). Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30: 1144-1152.
50. Zhang Z, Yu B, Tao G, (2009). Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin Med J 122: 2360-2365.